Drug Trial Radar · NCT06873945
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
674
Planned (sponsor's estimate)
Start
Apr 1, 2025
Primary completion
Mar 19, 2028
Study completion Mar 19, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is seeking participants who: * Are 12 years of age or older (Part 1) * Are 12 to less than 18 years (Part 2) * Have a diagnosis of alopecia areata * Have lost 50% or more of the hair on their scalp * Do not have any other conditions that causes hair loss * Are willing to stop all other treatments that they may be taking for alopecia areata About 550 participants will take part in Part 1 of this study. About 80 participants will take part in Part 2 of this study. In Part 1, participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily. The 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective. In Part 2, all eligible participants will receive ritlecitinib 100 mg taken by mouth once daily. The data from this part of the study will be combined with the data from Part 1 of the study to help to see if the 100 mg dose of ritlecitinib is safe and effective in adolescent patients with alopecia areata. People will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * alopecia areata assessment, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG (electrocardiogram), * photographs of the scalp and eyes (Part 1 only). Participants will also be asked to complete questionnaires about their alopecia areata.
Conditions
- Alopecia Areata
Interventions
Ritlecitinib 100 mgDrug
100 mg Capsule
Ritlecitinib 50 mgDrug
50 mg Capsule
Placebo - 100 mgDrug
Capsule (to match Ritlecitinib 100 mg)
Placebo - 50 mgDrug
Capsule (to match Ritlecitinib 50 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Percentage of participants with absolute Severity of Alopecia Tool (SALT) score less than or equal to 20Time frame: Week 24
- Part 2: Percentage of participants with TEAEs, SAEs, and AEs leading to discontinuationTime frame: Baseline to Follow-up visit (Week 52)
- Part 2: Percentage of participants with clinically significant laboratory abnormalitiesTime frame: Baseline to Follow-up visit (Week 52)
Locations
148 sites in 11 countries. Site status is shown where the registry gives one.
The Kirklin Clinic of UAB Hospital (Radiology)
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham Faculty Office Towers (Regulatory)
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Burke Pharmaceutical Research
Hot Springs, Arkansas · Active not recruiting
Doc1 Healthcare Systems
Brea, California · Recruiting
California Dermatology & Clinical Research Institute
Encinitas, California · Active not recruiting
Marvel Clinical Research
Huntington Beach, California · Active not recruiting
University of California - Irvine
Irvine, California · Recruiting
Gavin Herbert Eye Institute
Irvine, California · Recruiting
Southern California Clinical Research
Santa Ana, California · Active not recruiting
Brett King MD, LLC
Fairfield, Connecticut · Recruiting
Alliance for Multispecialty Research, LLC
Fort Myers, Florida · Active not recruiting
Robert B. Pritt, DO, PA
Fort Myers, Florida · Active not recruiting
Pediatric Skin Research
Miami, Florida · Recruiting
Skin Research of South Florida
Miami, Florida · Recruiting
ForCare Clinical Research
Tampa, Florida · Active not recruiting
Olympian Clinical Research - Tampa - Memorial Highway
Tampa, Florida · Active not recruiting
Endeavor Health Audiology -CHICAGO
Chicago, Illinois · Recruiting
Endeavor Health Audiology -LAKE BLUFF
Lake Bluff, Illinois · Recruiting
Endeavor Health Audiology-NORTHBROOK
Northbrook, Illinois · Recruiting
Endeavor Health Audiology-SKOKIE
Skokie, Illinois · Recruiting
Endeavor Health Imaging & Radiology Serviccs - Old Orchard
Skokie, Illinois · Recruiting
Endeavor Health Lab Services - Old Orchard
Skokie, Illinois · Recruiting
Endeavor Health
Skokie, Illinois · Recruiting
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Callender Center for Clinical Research
Glenn Dale, Maryland · Active not recruiting
Dermatology and Skin Cancer Specialists, LLC
Rockville, Maryland · Recruiting
Tufts Medical Center
Boston, Massachusetts · Active not recruiting
Massachusetts General Hospital
Boston, Massachusetts · Active not recruiting
The General Hospital Corporation d/b/a Massachusetts General Hospital
Boston, Massachusetts · Active not recruiting
Revival Research Institute, LLC
Troy, Michigan · Active not recruiting
University of Minnesota Clinics and Surgery Center Department of Radiology
Minneapolis, Minnesota · Recruiting
University of Minnesota Clinics and Surgery Center Department of Audiology
Minneapolis, Minnesota · Recruiting
University of Minnesota Clinics and Surgery Center Department of Radiology
Minneapolis, Minnesota · Recruiting
University of Minnesota Health Clinical Research Unit (M Health CRU)
Minneapolis, Minnesota · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina · Active not recruiting
Clinical & Translational Research Center (CTRC)
Chapel Hill, North Carolina · Active not recruiting
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.